Literature DB >> 22928164

The role of the TGF-β family in wound healing, burns and scarring: a review.

Jack W Penn1, Adriaan O Grobbelaar, Kerstin J Rolfe.   

Abstract

It is estimated worldwide that over 6 million people per annum experience a burn injury. Despite advances in management and improved survival rates, the incidence of hypertrophic scarring remains high. These scars are particularly common after burns and are often raised, red, hard and may cause abnormal sensations. Such pathological scarring can lead to severe functional impairment, psychological morbidity, and costly long term healthcare. Wound healing is an inherent process which restores the integrity of the skin after injury and although scarring is a frequent by-product, the scarless wound healing observed in early human gestational fetuses suggests that it is not an essential component of the response. This has lead to a large body of research attempting to understand the mechanisms behind scarring and in turn prevent it. One of the main focuses of recent research has been the role played by the growth factor TGF-β in the process of both wound healing and scar formation. The three isoforms (TGF-β1, TGF-β2 and TGF-β3) appear to have overlapping functions and predominantly mediate their effects through the intracellular SMAD pathway. Initial research suggested that TGF-β1 was responsible for the fibrotic scarring response whereas the scarless wound healing seen in fetal wounds was due to increased levels of TGF-β3. However, the reality appears to be far more complex and it is unlikely that simply altering the ratio of TGF-β isoforms will lead to scarless wound healing. Other aspects of the TGF-β system that appear promising include the downstream mediator CTGF, the proteoglycan decorin and the binding protein p311. Other putative mechanisms which may underlie the pathogenesis of hypertrophic scars include excessive inflammation, excessive angiogenesis, altered levels of matrix metalloproteinases, growth factors, and delayed apoptosis of fibrotic myofibroblasts either due to p53 genetic alterations or tensile forces across the wound. If an effective treatment for hypertrophic scars following burns injury is to be developed then further work must be carried out to understand the basic mechanisms of pathological scarring.

Entities:  

Keywords:  Burn scarring; TGF-β; hypertrophic scarring; pathological scarring; regeneration; wound healing

Year:  2012        PMID: 22928164      PMCID: PMC3415964     

Source DB:  PubMed          Journal:  Int J Burns Trauma        ISSN: 2160-2026


  104 in total

1.  Decorin interacts with connective tissue growth factor (CTGF)/CCN2 by LRR12 inhibiting its biological activity.

Authors:  Cecilia Vial; Jaime Gutiérrez; Cristian Santander; Daniel Cabrera; Enrique Brandan
Journal:  J Biol Chem       Date:  2011-03-23       Impact factor: 5.157

2.  Clinical applications of basic research that shows reducing skin tension could prevent and treat abnormal scarring: the importance of fascial/subcutaneous tensile reduction sutures and flap surgery for keloid and hypertrophic scar reconstruction.

Authors:  Rei Ogawa; Satoshi Akaishi; Chenyu Huang; Teruyuki Dohi; Masayo Aoki; Yasutaka Omori; Sachiko Koike; Kyoko Kobe; Masataka Akimoto; Hiko Hyakusoku
Journal:  J Nippon Med Sch       Date:  2011       Impact factor: 0.920

3.  Time course of the angiogenic response during normotrophic and hypertrophic scar formation in humans.

Authors:  Willem M van der Veer; Frank B Niessen; José A Ferreira; Peter J Zwiers; Etty H de Jong; Esther Middelkoop; Grietje Molema
Journal:  Wound Repair Regen       Date:  2011 May-Jun       Impact factor: 3.617

4.  Toll-like receptors expressed by dermal fibroblasts contribute to hypertrophic scarring.

Authors:  JianFei Wang; Keijiro Hori; Jie Ding; Yue Huang; Peter Kwan; Adil Ladak; Edward E Tredget
Journal:  J Cell Physiol       Date:  2011-05       Impact factor: 6.384

5.  Investigating the role of P311 in the hypertrophic scar.

Authors:  Jianglin Tan; Xu Peng; Gaoxing Luo; Bing Ma; Chuan Cao; Weifeng He; Shunzong Yuan; Shirong Li; John A Wilkins; Jun Wu
Journal:  PLoS One       Date:  2010-04-09       Impact factor: 3.240

6.  Attenuation of the transforming growth factor beta-signaling pathway in chronic venous ulcers.

Authors:  Irena Pastar; Olivera Stojadinovic; Agata Krzyzanowska; Stephan Barrientos; Christina Stuelten; Karen Zimmerman; Miroslav Blumenberg; Harold Brem; Marjana Tomic-Canic
Journal:  Mol Med       Date:  2010-01-06       Impact factor: 6.354

7.  Prophylactic administration of avotermin for improvement of skin scarring: three double-blind, placebo-controlled, phase I/II studies.

Authors:  Mark W J Ferguson; Jonathan Duncan; Jeremy Bond; James Bush; Piyush Durani; Karen So; Lisa Taylor; Jonquille Chantrey; Tracey Mason; Gaynor James; Hugh Laverty; Nick L Occleston; Abdul Sattar; Anna Ludlow; Sharon O'Kane
Journal:  Lancet       Date:  2009-04-11       Impact factor: 79.321

Review 8.  Transforming growth factor beta1 signalling, wound healing and repair: a multifunctional cytokine with clinical implications for wound repair, a delicate balance.

Authors:  B R Klass; A O Grobbelaar; K J Rolfe
Journal:  Postgrad Med J       Date:  2009-01       Impact factor: 2.401

9.  Matrix metalloproteinase-2 and -9 activities in human keloids, hypertrophic and atrophic scars: a pilot study.

Authors:  S Tanriverdi-Akhisaroglu; A Menderes; G Oktay
Journal:  Cell Biochem Funct       Date:  2009-03       Impact factor: 3.685

10.  Longitudinal changes in plasma Transforming growth factor beta-1 and post-burn scarring in children.

Authors:  Patricia Rorison; Alison Thomlinson; Zahid Hassan; Stephen A Roberts; Mark W J Ferguson; Mamta Shah
Journal:  Burns       Date:  2009-06-12       Impact factor: 2.744

View more
  182 in total

Review 1.  Epithelial-mesenchymal transition: An emerging target in tissue fibrosis.

Authors:  Meirong Li; Fuxin Luan; Yali Zhao; Haojie Hao; Yong Zhou; Weidong Han; Xiaobing Fu
Journal:  Exp Biol Med (Maywood)       Date:  2015-09-11

2.  miR-145 Contributes to Hypertrophic Scarring of the Skin by Inducing Myofibroblast Activity.

Authors:  Christiane Gras; Dominica Ratuszny; Catarina Hadamitzky; Haijiao Zhang; Rainer Blasczyk; Constança Figueiredo
Journal:  Mol Med       Date:  2015-04-09       Impact factor: 6.354

3.  Long non-coding RNA HOXA11-AS accelerates the progression of keloid formation via miR-124-3p/TGFβR1 axis.

Authors:  Jun Jin; Zhen-Hua Jia; Xiao-Hua Luo; Hong-Feng Zhai
Journal:  Cell Cycle       Date:  2019-12-27       Impact factor: 4.534

4.  Nanolayered siRNA delivery platforms for local silencing of CTGF reduce cutaneous scar contraction in third-degree burns.

Authors:  Steven A Castleberry; Alexander Golberg; Malak Abu Sharkh; Saiqa Khan; Benjamin D Almquist; William G Austen; Martin L Yarmush; Paula T Hammond
Journal:  Biomaterials       Date:  2016-04-14       Impact factor: 12.479

Review 5.  Thrombospondin-1 in ocular surface health and disease.

Authors:  William Foulsham; Thomas H Dohlman; Sharad K Mittal; Yukako Taketani; Rohan Bir Singh; Sharmila Masli; Reza Dana
Journal:  Ocul Surf       Date:  2019-06-05       Impact factor: 5.033

6.  Effects of red and near-infrared LED light therapy on full-thickness skin graft in rats.

Authors:  Cintia Cristina Santi Martignago; Carla Roberta Tim; Lívia Assis; Viviane Ribeiro Da Silva; Estefany Camila Bonfim Dos Santos; Fabiana Nascimento Vieira; Nivaldo Antonio Parizotto; Richard Eloin Liebano
Journal:  Lasers Med Sci       Date:  2019-06-05       Impact factor: 3.161

7.  Triple combination of siRNAs targeting TGFβ1, TGFβR2, and CTGF enhances reduction of collagen I and smooth muscle actin in corneal fibroblasts.

Authors:  Sriniwas Sriram; Paulette Robinson; Liya Pi; Alfred S Lewin; Gregory Schultz
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-12-17       Impact factor: 4.799

Review 8.  Cutaneous Scarring: Basic Science, Current Treatments, and Future Directions.

Authors:  Clement D Marshall; Michael S Hu; Tripp Leavitt; Leandra A Barnes; H Peter Lorenz; Michael T Longaker
Journal:  Adv Wound Care (New Rochelle)       Date:  2018-02-01       Impact factor: 4.730

9.  Fibromodulin Is Essential for Fetal-Type Scarless Cutaneous Wound Healing.

Authors:  Zhong Zheng; Xinli Zhang; Catherine Dang; Steven Beanes; Grace X Chang; Yao Chen; Chen-Shuang Li; Kevin S Lee; Kang Ting; Chia Soo
Journal:  Am J Pathol       Date:  2016-09-22       Impact factor: 4.307

10.  P311 promotes renal fibrosis via TGFβ1/Smad signaling.

Authors:  Zhihui Yao; Sisi Yang; Weifeng He; Lian Li; Rui Xu; Xiaorong Zhang; Haisheng Li; Rixing Zhan; Wei Sun; Jianglin Tan; Junyi Zhou; Gaoxing Luo; Jun Wu
Journal:  Sci Rep       Date:  2015-11-30       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.